PA-EXONE
24.6.2020 14:02:10 CEST | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced the launch of its updated Quick Ship metal 3D printing services, featuring a new digital quoting tool and materials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200624005137/en/
ExOne Quick Ship will now add the popular stainless steels 316L and 17-4PH to the list of materials offered through instant quoting, with delivery times of 10-15 business days, depending on number of units requested, part size, and other requirements.
“After two years of supplying thousands of 316L and 17-4 parts to select industrial customers, our updated Quick Ship services will now allow any customer to easily acquire and evaluate affordable single-alloy parts 3D printed with binder jetting,” said John Hartner, ExOne CEO.
A new Quick Ship online dashboard, available at www.exone.com/quickship , will allow customers to upload a qualifying digital design file for an instant quote and purchase, as well as create an account to track projects. More than 30 file types are accepted including STL and STP files.
Quick Ship parts will be 3D printed at ExOne’s metal production facility outside Pittsburgh, which has been binder jetting metal parts for more than two decades. It’s home to a fleet of more than two dozen metal 3D printers producing parts for prototype, low-volume, and serial production projects.
Quick Ship Service Represents Critical Progress
Binder jet 3D printing is a method of additive manufacturing in which an industrial printhead deposits a liquid binder onto a thin layer of powdered particles, layer by layer, until an object is formed. Parts printed in metal powders are then sintered in a furnace to fuse the particles.
In development since 1996, ExOne metal binder jet systems are capable of producing parts in more than 20 metals, ceramics and composite materials today. The technology is viewed as a disruptive and sustainable production method, largely because of its high speed, relatively low cost and material flexibility, among other benefits.
“The launch of Quick Ship services for single-alloy metals represents a key step forward in our development of metal binder jetting, and one that signifies our continued confidence in this technology,” said Rick Lucas, ExOne Chief Technology Officer and VP of New Markets. “We also have plans to expand the number of material offerings and size of printable parts in our Quick Ship services by year-end.”
Featured Quick Ship Metal 3D Printers
Quick Ship parts in 316L and 17-4PH will be 3D printed on ExOne’s Innovent+ and X1 25Pro metal 3D printing systems. Both machines feature ExOne’s exclusive Triple ACT system, an advanced compaction technology that delivers industry-leading density and repeatability in metal binder jetting. ExOne 3D printers with Triple ACT are capable of delivering sintered dimensional accuracy of +/- 2.5% on a first print run, with better results possible after additional sintering optimization.
ExOne will continue to offer its popular 316 and 420 materials infiltrated with bronze on its classic M-Flex and R2 metal 3D printing models, which have been in operation since 2013 and 2003, respectively. Infiltrated parts, which offer a variety of functionality and finish benefits, are typically shipped within 10 business days.
Other Materials Available Through Premium Quote
Metal, ceramic and composite materials not available through ExOne’s Quick Ship service will continue to be offered on a limited basis through ExOne’s Premium Quote service. Delivery times will vary based on the project details.
The full list of materials printable on ExOne 3D printing systems can be viewed at www.exone.com/metalmaterial . Materials such as M2 Tool Steel and Inconel 718 are available for quoting, and quote requests may depend on material availability.
About ExOne
ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com
or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200624005137/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
